Skip to main content
. 2021 Dec 20;12:791348. doi: 10.3389/fimmu.2021.791348

Figure 3.

Figure 3

The correlation between anti-MDA5 Ab and the outcome of COVID-19 patients. (A, B), Comparison of the titer and positive rate of anti-MDA5 Ab in COVID-19 patients with non-severe and severe performance. (C, D), The titer of anti-MDA5 Ab in COVID-19 patients with or without chronic comorbidities (C) and organ failure (D). (E, F), The titer (E) and positive rate (F) of anti-MDA5 Ab in the deceased patients with COVID-19. (G), Comparison of multiple variables in the survival and deceased patients with COVID-19 as shown in heatmap paragraphs. (H, I), The titer (H) and positive rate (I) of anti-MDA5 Ab in survival and dead patients with severe performance compared with that in the non-severe. (J), Comparison of the percentage of patients with high anti-MDA5 Ab (Unit value≥10.0 U/mL) in the survival and dead patients with severe performance. The numbers of COVID-19 patients in each group are indicated underneath. P values were determined by using unpaired, two-sided Mann-Whitney U-test and χ2 test. P < 0.05, *; P < 0.01, **; P < 0.0001, ****; ns, no significance.